The Use of Guarana to Treat Fatigue in Patients With Neuroendocrine Tumors and Gynecologic Cancers (Guarana Fatigue)

Part of paid clinical trials in Salt Lake City, Utah.

Sponsor
University of Utah
Study ID
NCT07151391
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Guarana — DRUG
    500 mg oral medication daily
  • Placebo — DRUG
    Oral medication daily

Study Details

The purpose of this clinical trial is to learn if the drug guarana improves symptoms of fatigue in patients with neuroendocrine tumors and gynecologic cancers

Key Dates

First listed
Sep 3, 2025
Start date
Sep 3, 2025
Status verified
Aug 2026
Primary completion
Sep 30, 2027
Completion
Sep 30, 2028

Study Design

Enrollment
86 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Guarana
    The study's goal is to determine the effect of Guarana on symptoms of fatigue
  • Placebo Comparator: Placebo
    The study's goal is to determine the effect of Guarana on symptoms of fatigue

Primary Outcome Measure

Stage 1 Primary Change in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Fatigue 12 (EORTC QLQ-FA12) questionnaire scores from screening to Day 21 of guarana treatment. [ Time Frame: up to 21 days after initiation of study intervention ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Huntsman Cancer Institute at University of UtahSalt Lake CityUtah84112
Susan Sharry
[email protected]
801-585-3453
Heloisa Soares, MD
[email protected]
801-215-0501

Find similar trials in Salt Lake City, UT

Nationwide
Neuroendocrine tumors trialsOncology trials
By condition
Neuroendocrine tumors
By specialty
Oncology
By research site
Huntsman Cancer Institute at University of Utah· Salt Lake City, UT

Related Studies